HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Jilly F Evans Selected Research

5-Lipoxygenase-Activating Proteins

12/2009Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation.
11/2009A novel 5-lipoxygenase-activating protein inhibitor, AM679, reduces inflammation in the respiratory syncytial virus-infected mouse eye.
10/20095-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103).
9/2004The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-dependent aortic aneurysm.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Jilly F Evans Research Topics

Disease

13Inflammation (Inflammations)
01/2020 - 08/2003
10Asthma (Bronchial Asthma)
01/2020 - 10/2003
5Neoplasms (Cancer)
12/2019 - 02/2003
5Allergic Rhinitis
11/2011 - 02/2008
4Lymphangioleiomyomatosis (Lymphangiomyomatosis)
11/2020 - 08/2010
3Lung Diseases (Lung Disease)
11/2020 - 01/2018
3Cardiovascular Diseases (Cardiovascular Disease)
01/2020 - 09/2004
3Pneumonia (Pneumonitis)
07/2011 - 12/2009
2Tuberous Sclerosis (Bourneville's Disease)
11/2020 - 01/2018
2Chronic Obstructive Pulmonary Disease (COPD)
08/2012 - 03/2010
2Myocardial Infarction
02/2008 - 09/2004
2Atherosclerosis
02/2008 - 08/2003
2Stroke (Strokes)
02/2008 - 09/2004
1Heart Diseases (Heart Disease)
01/2020
1Angiomyolipoma
01/2018
1Liver Cirrhosis (Hepatic Cirrhosis)
01/2017
1Fibrosis (Cirrhosis)
01/2017
1Melanoma (Melanoma, Malignant)
08/2016
1Allergic Conjunctivitis (Giant Papillary Conjunctivitis)
01/2012
1Atopic Dermatitis (Atopic Eczema)
07/2011
1Pneumothorax
08/2010
1Sneezing
07/2010
1Rhinorrhea
07/2010
1Pruritus (Itching)
07/2010
1Airway Remodeling
03/2010
1Metaplasia
03/2010
1Hyperplasia
03/2010
1Shock
12/2009
1Eye Diseases (Eye Disease)
11/2009
1Hypersensitivity (Allergy)
11/2009
1Vascular System Injuries
04/2006
1Down Syndrome Critical Region
04/2006

Drug/Important Bio-Agent (IBA)

6Proteins (Proteins, Gene)FDA Link
08/2012 - 02/2003
5LeukotrienesIBA
01/2020 - 05/2004
45-Lipoxygenase-Activating ProteinsIBA
12/2009 - 09/2004
3Mechanistic Target of Rapamycin Complex 1IBA
11/2020 - 01/2018
3lipoarabinomannan (LAM)IBA
11/2020 - 01/2018
3Messenger RNA (mRNA)IBA
08/2012 - 12/2005
3AllergensIBA
01/2012 - 10/2009
3prostaglandin D2 receptorIBA
11/2011 - 08/2009
3ProstaglandinsIBA
07/2011 - 02/2003
3OvalbuminIBA
07/2011 - 10/2009
3Arachidonate 5-Lipoxygenase (5 Lipoxygenase)IBA
11/2009 - 09/2004
2cysteinyl-leukotrieneIBA
01/2020 - 08/2012
2LipidsIBA
08/2014 - 09/2004
2leukotriene D4 receptor (cysteinyl leukotriene receptor)IBA
08/2012 - 12/2005
2Prostaglandins DIBA
07/2011 - 07/2010
2ZymosanIBA
08/2010 - 12/2009
2Blood Proteins (Serum Proteins)IBA
08/2010 - 12/2009
2propionic acid (potassium propionate)IBA
08/2010 - 12/2009
2Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
08/2010 - 02/2003
2Arachidonic Acid (Vitamin F)IBA
11/2009 - 07/2007
25-Lipoxygenase-Activating Protein InhibitorsIBA
11/2009 - 02/2008
2Cyclooxygenase 2 (Cyclooxygenase-2)IBA
04/2006 - 02/2003
2beta CateninIBA
08/2003 - 02/2003
2rofecoxib (Vioxx)FDA Link
08/2003 - 02/2003
1montelukast (Singulair)FDA Link
01/2020
1omipalisibIBA
12/2019
1trans-sodium crocetinate (crocetin)IBA
12/2019
1Cytostatic AgentsIBA
01/2018
1Insulin-Like PeptidesIBA
01/2018
1RNA (Ribonucleic Acid)IBA
01/2018
1Sirolimus (Rapamycin)FDA Link
01/2018
1Bleomycin (Blenoxane)FDA LinkGeneric
01/2017
1Choline (Choline Chloride)IBA
01/2017
1Phosphoric Diester Hydrolases (Phosphodiesterases)IBA
08/2016
1PyrophosphatasesIBA
08/2016
1Glucose-6-Phosphate Isomerase (Phosphoglucose Isomerase)IBA
08/2016
1lipoxin A4IBA
08/2014
1Nasal Decongestants (Decongestants)IBA
01/2012
1Histamine Antagonists (Antihistamines)IBA
01/2012
1Adrenal Cortex Hormones (Corticosteroids)IBA
01/2012
1Interleukin-4 (Interleukin 4)IBA
01/2012
1biphenylylacetic acid (felbinac)IBA
11/2011
1G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
07/2011
1Leukotriene B4IBA
08/2010
1Lipoxygenase (Lipoxygenase-1)IBA
08/2010
1Prolactin Receptors (Prolactin Receptor)IBA
08/2010
1ProlactinIBA
08/2010
1ramatrobanIBA
07/2010
1Thromboxane Receptors (Thromboxane Receptor)IBA
07/2010
1SmokeIBA
03/2010
1Eosinophil PeroxidaseIBA
12/2009
1Interleukin-5 (Interleukin 5)IBA
12/2009
13- (3- tert- butylsulfanyl- 1- (4- (6- methoxypyridin- 3- yl)benzyl)- 5- (pyridin- 2- ylmethoxy)- 1H- indol- 2- yl)- 2,2- dimethylpropionic acidIBA
12/2009
1Pharmaceutical PreparationsIBA
02/2008
1ThrombinFDA Link
04/2006
1Thromboplastin (Tissue Factor)IBA
04/2006
1Transcription Factors (Transcription Factor)IBA
04/2006
1Cytoplasmic and Nuclear Receptors (Nuclear Receptors)IBA
04/2006
1Metalloproteases (Metalloproteinases)IBA
04/2006
1Leukotriene D4IBA
04/2006
1ThrombospondinsIBA
04/2006
1LigandsIBA
04/2006
1Cycloheximide (Cicloheximide)IBA
04/2006
1DisintegrinsIBA
04/2006
1E-SelectinIBA
04/2006
1Matrix Metalloproteinase 2 (Gelatinase A)IBA
09/2004

Therapy/Procedure

4Therapeutics
01/2020 - 07/2007
1Oral Administration
01/2017